Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review
Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared w...
Saved in:
| Published in: | Journal of clinical oncology Vol. 36; no. 21; p. 2145 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
20.07.2018
|
| Subjects: | |
| ISSN: | 1527-7755, 1527-7755 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies. |
|---|---|
| AbstractList | Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies. Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies.Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for breast, brain, thyroid, skin, bone, and soft tissue malignancies). Alkylating and anthracycline chemotherapies increase the risk for development of several solid malignancies in addition to acute leukemia/myelodysplasia, and these risks may be modified by other patient characteristics, such as age at exposure and, potentially, inherited genetic susceptibility. Strategies for identifying survivors at risk and initiating long-term surveillance have improved and interventions are underway to improve knowledge about late-treatment effects among survivors and caregivers. Better understanding of treatment-related risk factors and genetic susceptibility holds promise for refining surveillance strategies and, ultimately, upfront cancer therapies. |
| Author | Morton, Lindsay M Oeffinger, Kevin C Hodgson, David C Henderson, Tara O Neglia, Joseph P Reulen, Raoul C van Leeuwen, Flora E Ronckers, Cecile M Yasui, Yutaka Turcotte, Lucie M |
| Author_xml | – sequence: 1 givenname: Lucie M surname: Turcotte fullname: Turcotte, Lucie M organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 2 givenname: Joseph P surname: Neglia fullname: Neglia, Joseph P organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 3 givenname: Raoul C surname: Reulen fullname: Reulen, Raoul C organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 4 givenname: Cecile M surname: Ronckers fullname: Ronckers, Cecile M organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 5 givenname: Flora E surname: van Leeuwen fullname: van Leeuwen, Flora E organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 6 givenname: Lindsay M surname: Morton fullname: Morton, Lindsay M organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 7 givenname: David C surname: Hodgson fullname: Hodgson, David C organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 8 givenname: Yutaka surname: Yasui fullname: Yasui, Yutaka organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 9 givenname: Kevin C surname: Oeffinger fullname: Oeffinger, Kevin C organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL – sequence: 10 givenname: Tara O surname: Henderson fullname: Henderson, Tara O organization: Lucie M. Turcotte, Joseph P. Neglia, University of Minnesota Medical School, Minneapolis, MN; Raoul C. Reulen, University of Birmingham, Birmingham, UK; Cecile M. Ronckers, Dutch Childhood Oncology Group Long-term Effects After Childhood Cancer Consortium, The Hague; Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Lindsay M. Morton, National Institutes of Health, Bethesda, MD; David C. Hodgson, University of Toronto, Toronto, Canada; Yutaka Yasui, St Jude Children's Research Hospital, Memphis, TN; Kevin C. Oeffinger, Duke University, Durham, NC; and Tara O. Henderson, University of Chicago Comer Children's Hospital, Chicago, IL |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29874133$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkElPwzAQhS1URBe4c0I-cmiC7XhJuFURZVGhUoFz5NgONaRxGydF_HsSKBKXmTfSN09vZgwGlasMAOcYhZggdPWQLkOCsAgFD4Xg9AiMMCMiEIKxwT89BGPv3xHCNI7YCRiSJBYUR9EI7FbWf0xhX-FcqsbVfgplpeFzW--NLUtZKQNd0c25N7vWVA18lKV9q2SnnozbltJvPLTVz4bddwY9nq5tqdfOaZj2DvU1nMGV2VvzeQqOC1l6c3boE_A6v3lJ74LF8vY-nS0CRTlpAk1oLqTOc2W01IJpnAiuExTHOWaR4iSSmFFcSKITESW0QIbnGGOhYoIUlWQCLn99t7Xrcvsm21ivTH-Rca3PCGKYMya46NCLA9rmG6OzbW03sv7K_t5EvgHqD2vn |
| CitedBy_id | crossref_primary_10_1007_s00520_020_05340_0 crossref_primary_10_1016_j_lssr_2021_06_002 crossref_primary_10_1016_j_ejca_2020_11_042 crossref_primary_10_1200_JCO_24_01519 crossref_primary_10_1093_ije_dyad124 crossref_primary_10_3390_jcm10071504 crossref_primary_10_1007_s11060_020_03478_9 crossref_primary_10_1159_000533571 crossref_primary_10_1016_j_jcis_2021_10_187 crossref_primary_10_3390_children5090119 crossref_primary_10_1007_s11764_021_01050_6 crossref_primary_10_1088_1361_6498_ac767b crossref_primary_10_1016_S1470_2045_19_30094_4 crossref_primary_10_1002_cncr_34110 crossref_primary_10_3389_fonc_2021_710163 crossref_primary_10_1016_j_chembiol_2021_08_014 crossref_primary_10_1001_jamanetworkopen_2024_36144 crossref_primary_10_1016_j_ijrobp_2019_05_025 crossref_primary_10_1093_nop_npaa039 crossref_primary_10_1159_000531241 crossref_primary_10_1002_ange_201911770 crossref_primary_10_1016_j_soncn_2021_151163 crossref_primary_10_3390_cancers16071297 crossref_primary_10_3390_ijms19113480 crossref_primary_10_1001_jamaoncol_2025_1340 crossref_primary_10_1093_jnci_djaa151 crossref_primary_10_1542_gr_43_4_46 crossref_primary_10_3390_ijms232416155 crossref_primary_10_1093_jncics_pkaa099 crossref_primary_10_1182_blood_2020007225 crossref_primary_10_1089_jayao_2020_0046 crossref_primary_10_1186_s13014_024_02515_5 crossref_primary_10_1002_cnr2_1984 crossref_primary_10_1210_endrev_bnad022 crossref_primary_10_1002_pbc_30551 crossref_primary_10_1158_1055_9965_EPI_24_0010 crossref_primary_10_1002_cncr_32325 crossref_primary_10_1016_j_phro_2021_11_008 crossref_primary_10_3390_cancers14235920 crossref_primary_10_1002_pbc_29962 crossref_primary_10_3390_ijms232112861 crossref_primary_10_1182_bloodadvances_2022008093 crossref_primary_10_1002_cam4_5835 crossref_primary_10_1016_j_clon_2021_04_010 crossref_primary_10_1016_j_radonc_2022_04_027 crossref_primary_10_1200_JCO_2018_79_0477 crossref_primary_10_5812_ijcm_127430 crossref_primary_10_1007_s40618_025_02555_y crossref_primary_10_1097_MPH_0000000000003001 crossref_primary_10_3389_fnut_2022_940514 crossref_primary_10_1016_j_neo_2025_101164 crossref_primary_10_1016_S2352_3026_21_00058_2 crossref_primary_10_1124_pr_118_016972 crossref_primary_10_1007_s00761_021_00957_0 crossref_primary_10_1001_jamanetworkopen_2020_13929 crossref_primary_10_1002_pbc_31271 crossref_primary_10_14338_IJPT_18_00009_1 crossref_primary_10_1016_j_rec_2020_11_020 crossref_primary_10_1016_j_ophtha_2020_05_024 crossref_primary_10_1016_j_nurpra_2022_01_022 crossref_primary_10_1080_17474086_2024_2370559 crossref_primary_10_1002_pbc_27656 crossref_primary_10_3390_cancers16050864 crossref_primary_10_2478_raon_2022_0027 crossref_primary_10_1016_S1470_2045_23_00461_8 crossref_primary_10_3390_ijerph17176136 crossref_primary_10_1016_j_jrras_2025_101616 crossref_primary_10_1016_j_pcl_2020_07_006 crossref_primary_10_1158_1078_0432_CCR_19_1822 crossref_primary_10_1038_s41375_025_02535_4 crossref_primary_10_1038_s41598_025_15553_0 crossref_primary_10_1158_1940_6207_CAPR_19_0416 crossref_primary_10_3390_ma14092135 crossref_primary_10_3390_cancers12113421 crossref_primary_10_1002_pbc_30494 crossref_primary_10_1007_s11938_020_00317_8 crossref_primary_10_1016_j_radonc_2022_08_027 crossref_primary_10_1200_PO_24_00668 crossref_primary_10_5694_mja2_50487 crossref_primary_10_1007_s00112_025_02267_w crossref_primary_10_1002_cncr_34723 crossref_primary_10_1002_jso_26478 crossref_primary_10_1158_0008_5472_CAN_20_0108 crossref_primary_10_1093_jncics_pkaa025 crossref_primary_10_1097_JXX_0000000000000474 crossref_primary_10_1038_s41571_023_00802_w crossref_primary_10_1002_anie_201911770 crossref_primary_10_1007_s00247_021_05023_w crossref_primary_10_1590_1518_8345_6302_3847 crossref_primary_10_1590_1518_8345_6302_3846 crossref_primary_10_1590_1518_8345_6302_3845 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2017.76.7764 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 29874133 |
| Genre | Journal Article Review |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c462t-d24b7adbbcedad75d1976d9088b153c623a1541fa2d97394f0e6b1117c820c4a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 103 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000439294100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Fri Sep 05 06:54:39 EDT 2025 Mon Jul 21 05:56:58 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-d24b7adbbcedad75d1976d9088b153c623a1541fa2d97394f0e6b1117c820c4a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://research.birmingham.ac.uk/en/publications/f7374f0b-bbef-4cd0-961c-058f46134606 |
| PMID | 29874133 |
| PQID | 2051655767 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2051655767 pubmed_primary_29874133 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-07-20 |
| PublicationDateYYYYMMDD | 2018-07-20 |
| PublicationDate_xml | – month: 07 year: 2018 text: 2018-07-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2018 |
| SSID | ssj0014835 |
| Score | 2.5825725 |
| SecondaryResourceType | review_article |
| Snippet | Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2145 |
| SubjectTerms | Cancer Survivors - statistics & numerical data Child Cohort Studies Humans Incidence Neoplasms, Second Primary - diagnosis Neoplasms, Second Primary - epidemiology Risk Risk Factors |
| Title | Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29874133 https://www.proquest.com/docview/2051655767 |
| Volume | 36 |
| WOSCitedRecordID | wos000439294100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF58IV58vx-MIJ4abZJNNvEipVhEbC1aobeyr0gR00fagv_emSTakyB42VN2CTuTybcz387H2EWS2EjGJnKkq6XDuSCZF60crarWxMKGicot_Sharajbjdtlwi0raZXfMTEP1GagKUeOh_TADQNEx-J2OHJINYqqq6WExiJb9hHKkFeL7ryKwKNcYJOUWxFFBkFZpkTHuH6oPxGvS1yJ8EoI6jfwG8DMfzSNjf--4iZbLyEm1Aqf2GILNt1mq82yiL7NLttFu-rPCnTmt6-yClxCe97I-nOHjZ772XsFaIRGoctTAZkaeJmOZ5bkitBjYJAARZ-ckj2BJuL6NyLXQIu46TL7yKCf5jP6M1yAHv9ppwx1WmF8AzUoahS77LVx16nfO6VEg6N56E0c43ElpFFKWyONCIyL8MYQd0phKNWIrSRiNDeRHhrej3lStaHC8Co0Ig_NpbfHltJBag8YxFqHinsyElpzEVg8uIW6GiTa9bm0Qh6y8-9d7-EnQHUNmdrBNOvN9_2Q7Rem6w2LXh09L44QM_n-0R9mH7M1dImIMrde9YQtJxgA7Clb0bNJPxuf5b6FY6vd_AK_9tqA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk%2C+Risk+Factors%2C+and+Surveillance+of+Subsequent+Malignant+Neoplasms+in+Survivors+of+Childhood+Cancer%3A+A+Review&rft.jtitle=Journal+of+clinical+oncology&rft.au=Turcotte%2C+Lucie+M&rft.au=Neglia%2C+Joseph+P&rft.au=Reulen%2C+Raoul+C&rft.au=Ronckers%2C+Cecile+M&rft.date=2018-07-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=36&rft.issue=21&rft.spage=2145&rft_id=info:doi/10.1200%2FJCO.2017.76.7764&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |